2025-522033-64-00招募中1 期
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor
Ajax Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2026年2月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 4
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
David Steensma
Scientific
Ajax Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.multiple myeloma2024-515219-23-00Centre Hospitalier Universitaire De Nantes35
已完成
不适用
A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in TurkeyNCT07357441Novartis Pharmaceuticals355
招募中
2 期
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MSMultiple sclerosis2023-507874-42-00Assistance Publique Hopitaux De Paris80
进行中（未招募）
不适用
Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsMyelofibrosisNCT07342712First Affiliated Hospital of Zhejiang University40
招募中
1 期
Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or
Myelodysplastic SyndromeAcute myeloid leukemia or Myelodysplastic
syndrome2024-513918-35-00Janssen Cilag International, Janssen Cilag International1